ArvinasARVN +0.36%70 OCF Yield % is -47.39 as of Jul. 01, 2026. GuruFocus rates ARVN with a GF Score™ of 70/100 and a GF Value™ of $11.89 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,415 Biotechnology companies, Arvinas ranks worse than 82.61% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Arvinas OCF Yield % Related Terms
Arvinas OCF Yield % Historical Data
* Premium members only.
The historical data trend for Arvinas's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arvinas's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arvinas OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arvinas's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Arvinas's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arvinas (ARVN) has a OCF Yield % of -47.39 as of Jul. 01, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Arvinas and its competitors. According to the industry distribution chart, Arvinas ranks #1169 out of 1415 companies in the Biotechnology industry, placing it in the top 82.6%.
Is Arvinas' OCF Yield % too high?
Arvinas' current OCF Yield % is -47.39. Based on the distribution chart, Arvinas ranks #1169 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arvinas has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arvinas' OCF Yield % compare to ZURA and KYTX?
According to the Biotechnology industry distribution chart, Arvinas ranks #1169 out of 1415 companies for OCF Yield %. This places Arvinas in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Arvinas and its competitors. Arvinas's current OCF Yield % is -47.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arvinas stock overvalued right now?
Based on GuruFocus' analysis, Arvinas (ARVN) is currently considered Possible Value Trap. The stock's GF Value™ is $11.89, compared to a current price of $8.31 — trading 30.1% below its estimated fair value. The current OCF Yield % is -47.39. Arvinas' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Arvinas (ARVN), the current OCF Yield % is -47.39 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arvinas (ARVN) Overvalued in 2026?
Based on GuruFocus' analysis, Arvinas stock appears to be undervalued.
The current stock price of $8.31 is trading 30.1% below its estimated GF Value™ of $11.89.
GuruFocus considers Arvinas to be Possible Value Trap.
Key valuation signals for ARVN:
OCF Yield %: -47.39
GF Value™: $11.89 vs. price of $8.31 (30.1% below fair value)
No single metric tells the full story. See the ARVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
70GF Score
Get the complete analysis for ARVN
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARVN has been successfully added to your 
